beacon trial: triplet therapy in braf v600e–mutated mcrc
Published 5 years ago • 857 plays • Length 6:01Download video MP4
Download video MP3
Similar videos
-
1:11
dr. kopetz on the rationale for the beacon crc study in braf v600e-mutant mcrc
-
1:45
breakwater: encorafenib plus cetuximab in patients with braf v600e-mutant mcrc
-
1:32
dr. flaherty on the rationale to explore triplet therapy in braf v600e-mutant melanoma
-
1:09
dr. kopetz on updated data from beacon crc study in braf v600e–mutant crc
-
0:54
dr. kopetz on safety data from beacon crc trial in braf v600e-mutant mcrc
-
3:25
first-line triplet in braf mcrc
-
5:04
beacon: encorafenib plus cetuximab with or without binimetinib for braf v600e–mutant metastatic ...
-
7:02
triplet regimens in braf-mutant metastatic crc
-
2:07
triplet regimen improves responses in braf v600e metastatic crc
-
1:51
dr. eng discusses the beacon crc study in braf-mutated crc
-
1:55
dr. lieu on the predictive value of braf v600e mutations in crc
-
2:24
real-world management of patients with braf-v600e mcrc
-
1:18
safety lead-in data for beacon crc trial with triplet biologic regimen in mcrc
-
2:18
prognosticating braf-mutant mcrc
-
9:28
new therapy options for braf-mutated mcrc
-
1:00
dr. kopetz discusses triplet therapy for braf-mutant crc
-
0:54
triplet therapy for certain patients with metastatic crc shows promise, but more research is needed
-
0:49
next steps after phase iii beacon crc trial in mcrc
-
1:18
how braf v600e-mutated crc is treated differently than other cancers